“The Predicting Effect of ASXL1 Mutation on BCR-ABL Transcript Types and Responses to Tyrosine Kinase Inhibitors in Patients with Chronic Myeloid Leukemia”, mfm, vol. 36, no. 8, Sep. 2025, doi: 10.60110/medforum.360805.